Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
*The following content is generated by AI and is for reference only.
Nilotinib base is a potent, selective inhibitor of the BCR-ABL tyrosine kinase, primarily utilized in the management of chronic myeloid leukemia (CML). Chemically identified by CAS number 641573-20-8, this compound serves as the active pharmaceutical ingredient (API) for various branded formulations. Its molecular formula is C26H29N7O2S, reflecting a complex structure designed to achieve high specificity against the abnormal kinase responsible for CML pathogenesis. The drug functions by binding to the ATP-binding site of the BCR-ABL protein, effectively halting the uncontrolled proliferation of leukemic cells. Nilotinib is particularly noted for its efficacy in patients who have developed resistance to or intolerance toward first-line therapies like imatinib. As a second-generation tyrosine kinase inhibitor, it demonstrates superior affinity for the BCR-ABL mutant compared to its predecessor, offering improved disease control and deeper molecular responses. Beyond clinical applications, nilotinib base is frequently employed in pharmaceutical research and development laboratories for preclinical studies, assay validation, and the synthesis of stable isotopically labeled standards used in pharmacokinetic profiling. The substance is supplied as a white to off-white crystalline powder, requiring strict storage conditions to maintain stability and potency. Regulatory agencies worldwide have approved nilotinib-based products for treating Philadelphia chromosome-positive chronic phase and accelerated phase CML, as well as blast crisis cases. Its mechanism involves not only inhibiting the primary oncogenic driver but also affecting downstream signaling pathways that promote cell survival. While highly effective, monitoring for potential side effects such as QT interval prolongation and metabolic disturbances remains critical during treatment protocols. The continued availability of nilotinib base ensures that researchers and manufacturers can produce essential medications for a significant patient population facing life-threatening hematological malignancies, solidifying its role as a cornerstone in modern oncology therapeutics.